In Vitro: iHCK-37 (5.0-20 μM; 24 hours) exhibits a potent in vitro?antiproliferative activity. The dose (μM) for growth inhibition (GI50) is 5.0-5.8?μM for AML cell lines (HL60, KG1a and U937) and 9.1-19.2?μM for chronic myeloid leukemia cell lines (HEL and K562).iHCK-37 (3-9 μM; plus Erythropoietin) leads to a decrease in ERK, AKT and P70S6K phosphorylation of in lentivirus HCK silenced K562 and U937 cell lines.iHCK-37 (3-9 μM) results in a decrease of p-HCK, p-ERK, p-AKT, p-70S6 in the cell line KG1a (AML/CD34+), in a dose-dependent manner.